# Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

> **NCT03757351** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 15 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** DNL747
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03757351
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-14
- **Primary completion:** 2020-06-18
- **Final completion:** 2020-06-18
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Due to change in Sanofi's development strategy for DNL747/SAR443060 - not due to any safety concerns
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757351, "Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03757351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*